Ignite Creation Date:
2024-05-05 @ 11:20 AM
Last Modification Date:
2024-10-26 @ 9:01 AM
Study NCT ID:
NCT00000435
Status:
COMPLETED
Last Update Posted:
2007-07-31
First Post:
2000-01-21
Brief Title:
dnaJ Peptide for Relieving Rheumatoid Arthritis
Sponsor:
National Institute of Arthritis and Musculoskeletal and Skin Diseases NIAMS
Organization:
National Institute of Arthritis and Musculoskeletal and Skin Diseases NIAMS
Study Overview
Official Title:
A Clinical Trial of Shared Epitope Peptides in Rheumatoid Arthritis RA
Status:
COMPLETED
Status Verified Date:
2007-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A small protein called dnaJ peptide may help people with rheumatoid arthritis RA by preventing their immune system cells from attacking their own tissues The purpose of this study is to determine if small amounts of dnaJ peptide can re-educate immune cells in people with RA so that the cells stop attacking joint tissues
Detailed Description:
Immune modulation is a promising new approach for the treatment of RA Studies have shown that immune cells in the joints of people in the early stages of RA react strongly against dnaJ peptides from bacteria These immune cells may also cross-react with human dnaJ peptides in the joints to cause inflammation dnaJ may help RA by re-educating the immune system and dampening the abnormal inflammatory immune response in RA
This study will last 7 months Participants will be randomly assigned to receive either dnaJ or placebo by mouth At screening participants will have medical history physical and medication assessment At screening at 6 study visits every month after the start of treatment and at 1 month follow-up participants will have a joint exam blood and urine collection and will fill out a questionnaire about their condition
This study will last 7 months Participants will be randomly assigned to receive either dnaJ or placebo by mouth At screening participants will have medical history physical and medication assessment At screening at 6 study visits every month after the start of treatment and at 1 month follow-up participants will have a joint exam blood and urine collection and will fill out a questionnaire about their condition
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NIAMS-042 | None | None | None |